🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524205-32-00
Completed Phase I

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis

2025-524205-32-00 · tracked via the Priya Life Science EU tracker
Sponsor
Regeneron Pharmaceuticals Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Skin and Connective Tissue Diseases
Decision date
30/04/2026
Enrollment target
115
Sites
Belgium, Czechia, Germany, Poland

Condition studied

Atopic Dermatits

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524205-32-00 on CTIS ↗ ← All trials in the EU